1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. RALLYBIO CORP
Rallybio Corp
XNAS: RLYB
16.93-0.15(-0.88%)
7,462
XNAS Volume

XNAS 07 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Board Meeting
The board meeting for Rallybio Corp is scheduled for today, for the purpose of Rallybio Corp Annual General Meeting for 2026See details

Rallybio Corp quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Rallybio Corp quarterly results: revenue, profit, and P&L – 13 quarter history

  • NEUTRAL

    Quarterly Revenue Rallybio Corp Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • POSITIVE

    Quarterly Net Profit Rallybio Corp Jun-2026 Quarterly Net Profit is $44 Million which is growth of 550.0% YoY.

Rallybio Corp, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
0.20.20.20.20.200.30.3
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
5.78.96.67.110.39.911.712.417.319.821.119.420.1
Operating Profit
-5.7-8.7-6.4-6.9-10.1-9.7-11.6-12.1-17-19.8-21.1-19.4-20.1
0.20.20.60.50.50.60.811.11.31.51.51.6
Profit Before Tax
45-8.3-5.916-9.4-9.4-11-11.5-16.2-19-20.2-18.4-18.4
Tax
1.3------------
⌄
43.7-8.3-5.916-9.7-9.4-11-11.5-16.2-19-20.2-18.4-18.6
Diluted NI Avail to Com Stockholders Ann.
43.7-8.3-5.916-9.7-9.4-11-11.5-16.2-19-20.2-18.4-18.6
Basic EPS
7.7-1.5-12.9-1.8-1.7-2-2.1-3-3.8-3.9-3.6-3.7
Diluted EPS After ExtraOrdinary
-0.8-1.5-12.9-1.8-1.7-2-2.1-3-3.8-3.9-3.6-3.7
Number Of Shares End
5.75.75.75.65.65.65.65.65.55.15.15.15.1
Net Income Continuing Discontinued Operations
43.7-8.3-5.916-9.7-9.4-11-11.5-16.2-19-20.2-18.4-18.6
Normalized Income
-4.9-8.3-5.916-9.7-9.4-11-11.5-16.2-19-20.2-18.4-18.6
Interest Income
0.20.20.60.50.50.60.811.11.31.51.51.6
Interest
-------------
Net Interest Income
0.20.20.60.50.50.60.811.11.31.51.51.6
EBIT
-5.7-8.7-6.4-6.9-10.1-9.7-11.6-12.1-17-19.8-21.1-19.4-20.1
EBITDA
-5.7-8.7-6.4-6.9-10-9.6-11.6-12-17-19.8-21.1-19.3-20.1
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
0000000000
Profit From Continuing Operations
43.7-8.3-5.916-9.7-9.4-11-11.5-16.2-19-20.2-18.4-18.6
Normalized EBITDA
-55.7-8.7-6.4-6.9-10-9.6-11.6-12-17-19.8-21.1-19.3-20.1
*All financials are in USD Million and price data in USD

Rallybio Corp competitor comparison and performance snapshot within industry

Rallybio Corp annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

  • POSITIVE

    Annual Revenue Rallybio Corp Dec-2025 Annual Revenue is $1 Million which is growth of 34.9% YoY.

  • POSITIVE

    Annual Net Profit Rallybio Corp Dec-2025 Annual Net Profit is $-9 Million which is growth of 84.5% YoY.

Rallybio Corp, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
-
-
 0.90.6
Cost Of Rev. Ann.
-
-
 -------
Gross Profit Ann.
-
-
 -------
Operating Exp. Ann.
-20.7%
6%
28.433.961.178.967.945.725.317.6
Operating Profit Ann.
-
-
-27.7-33.1-60.5-78.9-67.9-45.7-25.3-17.6
3.2%
85.6%
1.42.24.26.2200.10.2
Other Exp. Ann.
317.9%
155.8%
 21.9-1.5-1.80.30.10.20
PBT Ann.
-
-
46.9-9-57.8-74.6-65.6-45.5-24.9-17.5
Tax Ann.
-
-
 -----0
⌄
-
-
45.6-9-57.8-74.6-66.7-47-26.5-17.6
Diluted NI Avail to Com Stockholders Ann.
-
-
45.6-9-57.8-74.6-66.7-47-26.5-17.6
EPS Ann.
-
-
 -1.6-10.6-14.7-16.7-14.7-12.2-8.1
Diluted EPS Ann.
-
-
 -1.6-10.6-14.7-16.7-14.7-12.2-8.1
Number Of Shares End
8.2%
15.3%
 5.75.65.14.53.82.8-
Total Exp. Ann.
-20.7%
6%
 33.961.178.967.945.725.317.6
Net Income Continuing Discontinued Operations Ann.
-
-
45.6-9-57.8-74.6-66.7-47-26.5-17.6
Normalized Income Ann.
-
-
-3-9-57.8-74.6-66.7-47-26.5-17.6
Interest Income Ann.
3.2%
61.5%
1.42.24.26.220.10.20.2
Interest Ann.
-
-
 ---00.10
EBITDA Ann.
-
-
-27.7-33-60.4-78.8-65.4-45.4-24.8-17.4
Reconciled Cost Of Rev. Ann.
-
-
 -------
Reconciled Depr. Ann.
-20.6%
0%
00.10.10.20.20.10.10
Profit From Continuing Operations Ann.
-
-
45.6-9-57.8-74.6-66.7-47-26.5-17.6
Normalized EBITDA Ann.
-
-
-77.7-33-60.4-78.8-65.4-45.4-24.8-17.4
*All financials are in USD Million and price data in USD
Total Rev. Ann.
1Y CHG
50%
Operating Exp. Ann.
1Y CHG
-44.5%
2Y CAGR
-34.5%
3Y CAGR
-20.7%
5Y CAGR
6%

Rallybio Corp balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

  • NEGATIVE

    Total Shareholders Fund Rallybio Corp Dec-2025 Total Shareholders Fund is $58 Million which is growth of -6.0% YoY.

  • NEGATIVE

    Total Assets Rallybio Corp Dec-2025 Total Assets is $62 Million which is growth of -8.6% YoY.

Rallybio Corp, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
-29.8%
-15.2%
62.368.1115.6180.4182.2141.921.6
⌄
-27.1%
-53%
4.36.59.411.16.6187.941.9
⌄
-30%
-
5861.7106.2169.3175.6-46-20.3
Total Capitalization Ann.
-30%
-
5861.7106.2169.3175.6-46-20.3
Tangible Assets Ann.
-30%
-
5861.7106.2169.3175.6
Working Capital Ann.
-30.4%
-15.9%
5761.6105.5168.8174.3135.417.1
Invested Capital Ann.
-30%
-
5861.7106.2169.3175.6-46-20.3
Tangible Book Value Ann.
-30%
-
5861.7106.2169.3175.6-46-20.3
Borrowings Ann.
-30.7%
-
0.20.20.40.6---
Net Debt Ann.
-
-
-------
Share Issued Ann.
4.1%
6.9%
5.35.24.74.743.83.8
Number Of Shares End
8.2%
15.3%
5.75.65.14.53.82.8-
*All financials are in USD Million and price data in USD
Total Assets Ann.
1Y CHG
-8.5%
2Y CAGR
-26.6%
3Y CAGR
-29.8%
5Y CAGR
-15.2%
Total Current Liabilities Ann.
1Y CHG
-32.3%
2Y CAGR
-32.8%
3Y CAGR
-26.8%
5Y CAGR
-6.3%
Total ShareHolders Funds Ann.
1Y CHG
-6%
2Y CAGR
-26.1%
3Y CAGR
-30%

Rallybio Corp ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

  • POSITIVE

    Book Value Per Share Rallybio Corp Book Value Per Share is $18 which is growth of 102.2% YoY.

  • NEUTRAL

    ROE Rallybio Corp ROE is 0% which is growth of 0% YoY.

Rallybio Corp, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
RoA Ann. %
-
-
--62.89%-50.37%-36.76%-29.02%-32.36%-81.28%
ROE Ann. %
-
-
--68.85%-54.13%-38.65%-72.56%--
ROIC %
-
-
--17.9-18.8-11.4-6.9--
OPM Ann. %
-
-
-3,853.61%-9,511.95%-----
Inventory Turnover Ratio Ann.
-
-
-------
Asset Turnover Ann. %
-
-
-0-----
Working Capital Turnover Ann.
-
-
00
Quick Ratio Ann.
-
-
-10.511.915.726.8245.1
Current Ratio Ann.
-
-
-10.912.416.727.624.25.5
Interest Coverage Ratio Ann.
-
-
-----4,549.8-508-446.7
LT Debt To Equity Ann.
-
-
-----
*All financials are in USD Million and price data in USD

Rallybio Corp cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

  • POSITIVE

    Cash From Operating Activity Rallybio Corp Dec-2025 Cash From Operating Activity is $-30 Million which is growth of 39.5% YoY.

  • POSITIVE

    Net Cash Flow Rallybio Corp Dec-2025 Net Cash Flow is $17 Million which is growth of 265.0% YoY.

Rallybio Corp, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
-
-
-29.8-49.3-60.3-57.3-45.5-22-15
-
-
47.333.527.7-112.2-2.3-2.1-0.2
-
-
05.20.151.183144.931.6
Cash Plus Cash Eqv. End Of Year Ann.
-18%
-25.9%
31.413.924.557175.3140.219.5
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-32%
17.5-10.6-32.5-118.435.1120.816.4
Cash Plus Cash Eqv. Begin Of Year Ann.
-57%
-6.5%
13.924.557175.3140.219.53.1
Income Tax Paid Supplemental Data Ann.
-
-
-------
Interest Paid Supplemental Data Ann.
-
-
-------
Capex Ann.
-
-
---0-0.1-0.3-0.1-0.2
Issuance Of Capital Stock Ann.
-60.3%
-29.8%
5.451.586.2145.231.6
Issuance Of Debt Ann.
-
-
-------
Repayment Of Debt Ann.
-
-
-------
Repurchase Of Capital Stock Ann.
-
-
-------
Free Cash Flow Ann.
-
-
-29.8-49.3-60.3-57.3-45.9-22.2-15.2
*All financials are in USD Million and price data in USD
Cash from Investing Act. Ann.
1Y CHG
41.2%
2Y CAGR
30.7%